
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    To annotate the cell type from the provided ranked marker list, I will follow the outlined steps to ensure a comprehensive analysis.<br><br>### Step 1: List the Key Functional Markers<br>- **IGFBP5, IGFBP2**: Insulin-like growth factor binding proteins, involved in modulating IGF actions, which are crucial in cell growth, differentiation, and apoptosis.<br>- **ERBB2 (HER2)**: A member of the epidermal growth factor receptor (EGFR) family, often overexpressed in certain breast cancers, playing a role in cell proliferation and survival.<br>- **AR (Androgen Receptor)**: A nuclear receptor that is activated by binding any of the androgenic hormones, involved in the regulation of genes related to cell growth.<br>- **GRB7**: An adaptor protein that interacts with receptor tyrosine kinases and is involved in signal transduction pathways that regulate cell migration and proliferation.<br>- **TNFSF10 (TRAIL)**: A cytokine that induces apoptosis, particularly in cancer cells.<br>- **JUND**: A component of the AP-1 transcription factor complex, involved in regulating gene expression in response to a variety of stimuli, including stress and growth factors.<br><br>### Step 2: List the Key Cell Type Markers<br>- **ERBB2 (HER2)**: Strongly associated with breast cancer cells, particularly HER2-positive breast cancer.<br>- **AR (Androgen Receptor)**: While more commonly associated with prostate cancer, AR is also expressed in some breast cancer subtypes.<br>- **IGFBP5, IGFBP2**: Often expressed in breast tissue and associated with breast cancer progression.<br>- **RBP1**: Retinol-binding protein, involved in vitamin A metabolism, which can be relevant in breast tissue differentiation and cancer.<br>- **TRPS1**: A transcription factor involved in the regulation of cell proliferation and differentiation, known to be expressed in breast tissue.<br><br>### Step 3: Cross-reference Known Databases<br>Using databases such as the Human Protein Atlas, CellMarker, and literature on breast cancer scRNA-seq, the following observations can be made:<br>- **ERBB2 (HER2)** is a well-known marker for HER2-positive breast cancer.<br>- **IGFBP5 and IGFBP2** are frequently associated with breast cancer and are involved in the regulation of cell growth and apoptosis.<br>- **AR** expression in breast cancer is indicative of a subtype that may respond to hormonal therapies.<br><br>### Step 4: Determine the Most Probable General Cell Type<br>Based on the expression of **ERBB2 (HER2)**, **IGFBP5**, **IGFBP2**, and **AR**, the most probable general cell type is **breast cancer epithelial cells**, specifically those associated with HER2-positive breast cancer.<br><br>### Step 5: Identify the Top 3 Most Probable Sub Cell Types<br>1. **HER2-positive Breast Cancer Cells**: Due to the high expression of ERBB2 (HER2), which is a defining marker.<br>2. **Luminal Breast Cancer Cells**: Characterized by the expression of AR and IGFBPs, which are often seen in luminal subtypes.<br>3. **Basal-like Breast Cancer Cells**: Although less likely due to the lack of typical basal markers, the presence of growth factor-related genes could suggest a basal-like phenotype.<br><br>The most likely subtype based on the markers is **HER2-positive Breast Cancer Cells**.<br><br>### Step 6: Provide a Concise Summary of Your Analysis<br>The analysis of the ranked marker list from the breast cancer tissue dataset suggests that the cell cluster is most likely composed of **HER2-positive breast cancer epithelial cells**. This conclusion is supported by the high expression of ERBB2 (HER2), along with other markers such as IGFBP5, IGFBP2, and AR, which are associated with breast cancer cell proliferation and survival. The presence of these markers aligns with known characteristics of HER2-positive breast cancer, making it the most probable cell type.<br><br>FINAL ANNOTATION COMPLETED
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED<br><br>The proposed annotation result is consistent with the provided marker list and the identified cell type. Here's the breakdown:<br><br>1. **Marker Consistency**:<br>   - The key functional markers and cell type markers mentioned in the annotation (IGFBP5, IGFBP2, ERBB2, AR, GRB7, TNFSF10, JUND, RBP1, TRPS1) are all present in the provided marker list.<br>   - The markers used to identify the cell type as HER2-positive breast cancer epithelial cells are consistent with known markers for this cell type.<br><br>2. **Mixed Cell Type Consideration**:<br>   - The annotation considers the possibility of different breast cancer subtypes (HER2-positive, Luminal, Basal-like) based on the expression of the markers. However, the strongest evidence supports the HER2-positive subtype, which is appropriate given the high expression of ERBB2 (HER2).<br>   - There is no strong evidence of mixed cell types that would necessitate further investigation.<br><br>The annotation is well-supported by the marker list and aligns with known characteristics of HER2-positive breast cancer cells.
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">breast cancer epithelial cells</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>HER2-positive Breast Cancer Cells</li><li>Luminal Breast Cancer Cells</li><li>Basal-like Breast Cancer Cells</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li class="empty-list">No mixed cell types identified</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">90</div>
                        <div class="scoring-content">
                            The annotation results provided demonstrate a strong understanding of the markers and their relevance to breast cancer, particularly HER2-positive breast cancer. The analysis correctly identifies key markers such as ERBB2 (HER2), IGFBP5, and IGFBP2, which are well-known to be associated with breast cancer, especially the HER2-positive subtype. The inclusion of AR and its relevance to certain breast cancer subtypes is also appropriate, as AR is expressed in some breast cancer types and can influence treatment strategies.<br><br>The annotation process shows a balanced consideration of multiple markers, not overly focusing on a single one, which is crucial for accurate cell type identification. The analysis also considers the possibility of different breast cancer subtypes, such as Luminal and Basal-like, which demonstrates a comprehensive approach to understanding the cell populations present.<br><br>However, there are a few areas where the analysis could be improved. While the annotation correctly identifies HER2-positive breast cancer cells as the most likely subtype, it could have provided more detailed reasoning for the exclusion of other potential subtypes, especially given the presence of markers like JUND and GRB7, which could be relevant to other cancer pathways. Additionally, the rank of the markers was not explicitly considered in the analysis, which could have provided further insight into the relative importance of each marker in the dataset.<br><br>Overall, the annotation is scientifically accurate and provides a comprehensive view of the cell types present, with a strong focus on the most probable subtype. There are no obvious misclassifications, and the analysis aligns well with known characteristics of breast cancer markers.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    